Company intelligence / Profile preview

JangoBio

Fitchburg, Wisconsin, United Statesjango.bio ↗

Ownership: Private
Development stage: Preclinical

Overview

JangoBio has developed a regenerative medicine platform using stem cell-derived organoids to restore hormone balance by regenerating gonadal tissues. Their lead program "Jango-Renew" targets the veterinary market for age-related hormonal decline in pets. The company reports ongoing enrollment of a pilot veterinary clinical study with preliminary data expected late 2025. Human therapeutic programs remain at the preclinical stage.

Therapeutic areas: OtherEndocrinology
Modalities: Stem cell therapyOrganoid-based therapyCell therapy
Industry: Biotech

Drug pipeline

3 assets

Jango-Org-C1

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

None publicly disclosed as of June 2025.

Beyond the preview

Go deeper on JangoBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JangoBio.

Explore the full profile